Autoimmune Features of Neurodegenerative Disorders

Korábbi kezelés

• Atypical features indicative of a Parkinson-Plus disorder (Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD)) including cerebellar signs, supranuclear gaze palsy, apraxia and other cortical signs, or prominent autonomic failure, neuroleptic treatment at time of onset of parkinsonism, active treatment with a neuroleptic at time of study entry, history of repeated strokes with stepwise progression of parkinsonism, history of repeated head injury, history of definite encephalitis, prominent gait imbalance early in the course (\< 5 years)
• On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)
• On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)
• On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)
• On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)

Más betegség

• History of Dementia
• Recent history of cancer (past 3 years), except skin cancer
• Autoimmune disease
• Disease of the immune system (e.g. chronic leukemia, HIV)
• Recent history of cancer (past 3 years), except skin cancer
• Autoimmune disease
• Disease of the immune system (e.g. chronic leukemia, HIV)
• Other forms of dementia including frontotemporal dementia or other dementia associated with parkinsonism such as Dementia with Lewy bodies (DLB), or Parkinson's disease Dementia (PDD), Progressive Supranuclear Palsy or corticobasal degeneration.
• History of Parkinson's disease (PD)
• Recent history of cancer (past 3 years), except skin cancer
• Autoimmune disease
• Disease of the immune system (e.g. chronic leukemia, HIV)
• History of Parkinson's disease (PD)
• Recent history of cancer (past 3 years), except skin cancer
• Autoimmune disease
• Disease of the immune system (e.g. chronic leukemia, HIV)

Életkor

• Inability to provide informed consent.
  • For age-matched control participants (n=30):
• Inability to provide informed consent
  • AD/aMCI and age matched controls:
  • For AD/aMCI participants (n=30):
• Inability to provide informed consent
  • For age-matched control participants (n=30):

Egyéb

• Inability to provide informed consent

• Clinical diagnosed PD based on UK Brain Bank criteria for the clinical diagnosis of PD. And must demonstrate two of the following three, as modified from BioFIND criteria: rest tremor, rigidity, or bradykinesia, with dopaminergic medication benefit
• Age at recruitment ≥ 55
• Age at motor onset \> 45
• PD onset age between 50-75 years
• Willingness to have genotyping and genetic studies
• Ages ≥55 years old
• With lack of PD in first-degree blood relatives
• Montreal Cognitive Assessment (MoCA): ≥26
• Willingness to have genotyping and genetic studies
• Clinically diagnosed mild AD/amnestic MCI. The severity will be accessed through the Clinical Dementia Rating Scale (CDR). CDR equal to 0.5 or 1 will be necessary to meet criteria. Participants with advanced AD stage will not be capable to give their consent.
• Age ≥55 years old
• Mini-Mental State Exam (MMSE): 20-26
• Willingness to have genotyping and genetic studies
• Healthy volunteers ≥55 years old
• CDR: 0
• MoCA: ≥26
• Willingness to have genotyping and genetic studies

A regiszterben nem jelölt feltételek

• PD and age matched controls:
• For PD participants (n=30):